RNA-targeted Alzheimer's disease therapeutic - Ionis Pharmacetical/Roche
Latest Information Update: 18 Mar 2026
At a glance
- Originator Ionis Pharmaceuticals
- Developer Roche
- Class Antidementias
- Mechanism of Action RNA modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease